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Abstract
Background: In a neonatal model of hypoxic pulmonary hypertension, a dramatic pulmonary artery adventitial thickening,
accumulation of inflammatory cells in the adventitial compartment, and angiogenic expansion of the vasa vasorum
microcirculatory network are observed. These pathophysiological responses suggest that rapidly proliferating vasa vasorum
endothelial cells (VVEC) may exhibit increased permeability for circulating blood cells and macromolecules. However, the
molecular mechanisms underlying these observations remain unexplored. Some reports implicated extracellular adenosine
in the regulation of vascular permeability under hypoxic and inflammatory conditions. Thus, we aimed to determine the role
of adenosine in barrier regulation of VVEC isolated from the pulmonary arteries of normoxic (VVEC-Co) or chronically
hypoxic (VVEC-Hyp) neonatal calves.
Principal Findings: We demonstrate via a transendothelial electrical resistance measurement that exogenous adenosine
significantly enhanced the barrier function in VVEC-Co and, to a lesser extent, in VVEC-Hyp. Our data from a quantitative
reverse transcription polymerase chain reaction show that both VVEC-Co and VVEC-Hyp express all four adenosine receptors
(A1, A2A, A2B, and A3), with the highest expression level of A1 receptors (A1Rs). However, A1R expression was significantly
lower in VVEC-Hyp compared to VVEC-Co. By using an A1R-specific agonist/antagonist and siRNA, we demonstrate that
A1Rs are mostly responsible for adenosine-induced enhancement in barrier function. Adenosine-induced barrier integrity
enhancement was attenuated by pretreatment of VVEC with pertussis toxin and GSK690693 or LY294002, suggesting the
involvement of Gi proteins and the PI3K-Akt pathway. Moreover, we reveal a critical role of actin cytoskeleton in VVEC
barrier regulation by using specific inhibitors of actin and microtubule polymerization. Further, we show that adenosine
pretreatment blocked the tumor necrosis factor alpha (TNF-a)-induced permeability in VVEC-Co, validating its anti-
inflammatory effects.
Conclusions: We demonstrate for the first time that stimulation of A1Rs enhances the barrier function in VVEC by activation
of the Gi/PI3K/Akt pathway and remodeling of actin microfilament.
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Introduction
Pathological vascular remodeling plays a pivotal role in the
progression of a variety of pulmonary vascular diseases, including
pulmonary hypertension [1]. Moreover, many pulmonary vascular
diseases are associated with lung exposure to hypoxia and
subsequent development of the inflammatory, fibrotic, and
angiogenic responses in the vasculature [2,3,4,5]. The vasa vasorum
is a microcirculatory network that provides oxygen and nutrients
to the adventitial and medial compartments of large blood vessels.
Although it was originally recognized as the main guardian of
vascular integrity, the vasa vasorum has recently emerged as an
important contributor to the initiation and progression of vascular
diseases, through processes of angiogenesis and vasculogenesis
[6,7,8]. Our recent data in a neonatal model of pulmonary
hypertension showed that angiogenic expansion of the vasa vasorum
network can be observed in the pulmonary arteries of chronically
hypoxic calves, and that this process is accompanied by marked
adventitial thickening, as well as infiltration and homing of
circulating inflammatory cells in the pulmonary artery vascular
wall [1,9,10].
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e59733The vascular endothelium is recognized as an active part of the
vasculature due to its secretory and adhesive properties [11,12].
Moreover, the endothelium is a semi-selective diffusion barrier
regulating a variety of functions, including the passage of
macromolecules and fluids between the blood and the interstitial
fluid. Defects in some physiological functions of the endothelium
lead to inflammatory lung disorders, such as pulmonary hyper-
tension and acute lung injury. Elevated expression of intercellular
adhesion molecule-1 (ICAM-1) by tumor necrosis factor-alpha
(TNF-a) has been described as an important mechanism of
leukocyte sequestration in the pulmonary microvasculature in
patients with acute lung inflammation [13].
The role of extracellular purine nucleotides (ATP and ADP) and
adenosine as important regulators of vascular cell function is well
recognized [9,14,15,16,17,18]. Adenosine is produced in response
to metabolic stress and cell damage, and its levels are elevated in
ischemia, hypoxia, inflammation, and trauma [19]. The dominant
sources of extracellular adenosine are mainly ATP and ADP that
are hydrolyzed by the combined action of ecto-enzymes, CD39/
NTPDase-1 and CD73/ecto-59-nucleotidase [20,21,22]. Extracel-
lular adenosine binds to P1, G protein-coupled adenosine
receptors (A1, A2A, A2B, and A3) that have been pharmacolog-
ically well characterized [23,24]. Activation of A1 and A3
receptors leads to a decrease in cAMP concentration via inhibition
of adenylate cyclase and to a raise in intracellular Ca
2+ levels by
a pathway involving phospholipase C activation [23,25]. In
contrast, stimulation of A2A and A2B receptors leads to activation
of adenylate cyclase and generation of cAMP, whose role in the
regulation of cell barrier function is well characterized [19,26].
Adenosine can activate A1, A2A, and A3 receptors with EC50 of
0.2–0.7 mM range, whereas the potency of adenosine toward A2B
receptors is much lower (EC50:2 4 mM) [25]. This receptor
complexity reflects the multifaceted role played by adenosine in
health and disease, including inhibiting of pro-inflammatory
responses and preventing excessive tissue damage [24,27].
Extracellular adenosine has been implicated in the regulation of
vascular permeability and inflammation in the vasculature
[22,28,29,30]. Studies on CD73(2/2) mice provided evidence
that extracellular adenosine reversed hypoxia-induced vascular
leakage in different organs, especially in the lung [22]. In addition,
studies on adenosine receptor subtype-specific knockout mice
demonstrated that this protective effect of adenosine is mediated
by A2B receptors [30]. In contrast, activation of A3 receptors with
adenosine resulted in increased cutaneous vascular permeability
[29]. The key regulatory role of ecto-59-nucleotidase/CD73 and
adenosine in controlling the endothelial barrier function in vitro has
been supported by studies on transendothelial leukocyte migration
[31,32,33,34]. Complementary to these observations, hypoxia-
induced vascular leak can be attenuated by an increase in the level
of extracellular adenosine due to HIF-1a–dependent repression of
adenosine kinase, an enzyme catalyzing adenosine phosphoryla-
tion to AMP, and thereby [35]. Since extracellular adenosine is an
important physiological regulator of vascular permeability and
inflammation, this study was undertaken to further elucidate the
adenosine receptor-mediated signaling contributing to VVEC
barrier integrity. Our data demonstrate that extracellular adeno-
sine, acting mostly through A1Rs, enhanced the barrier function
in VVEC via the mechanisms that involve Gi/PI3K/Akt signaling
and actin cytoskeleton remodeling.
Figure 1. Proliferation of VVEC-Co and VVEC-Hyp in ECIS
arrays. Equal numbers of VVEC-Co and VVEC-Hyp (100,000 cells/well)
were seeded in ECIS arrays and the TER was measured for 36 h. Results
are presented as mean 6 SEM and derived from three independent
experiments.
doi:10.1371/journal.pone.0059733.g001
Figure 2. Adenosine enhances the VVEC barrier function. VVEC
monolayers in ECIS arrays were incubated in serum free medium for 1 h.
Adenosine (50–500 mM) was added to VVEC-Co (A) or VVEC-Hyp (B)
after a steady baseline was established, and the TER measurements
continued for 6 h. Data are representative of multiple independent
experiments (minimum of three).
doi:10.1371/journal.pone.0059733.g002
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Materials
siPORT Amine transfection reagent was purchased from
Ambion (Austin, TX). Adenosine A1 receptor antibody (sc-
28995), A1R-specific small interfering ribonucleic acid (siRNA),
and horseradish peroxidase-conjugated goat anti-rabbit IgG
antibody were procured from Santa Cruz Biotechnology (Santa
Cruz, CA). TRIzol was obtained from Invitrogen (Carlsbad, CA).
Anti-phospho-Akt (Ser473) and anti-tubulin antibodies were
obtained from Cell Signaling Technology (Danvers, MA). An
enhanced chemiluminescence detection kit (ECL) was purchased
from Amersham (Little Chalfont, UK). Endothelial cell growth
supplement was obtained from Millipore (Billerica, MA). The
GSK690693 (Akt inhibitor), LY294002 (PI3K inhibitor), adeno-
sine receptors-specific agonists and antagonists were obtained from
Tocris Bioscience (Ellisville, MI). Alexa Fluor 488 Phalloidin (Cat
# A12379) was purchased from Invitrogen. All other reagents
were obtained from Sigma-Aldrich (St. Louis, MO).
Isolation and culture of VVEC
VVEC were isolated from the pulmonary artery adventitia of
normoxic (two-week kept at ambient Denver altitude;
PB=640 mmHg) and chronically hypoxic (two-week exposed to
hypobaric hypoxia; PB=430 mmHg) male Holstein calves as
previously described [9]. Standard veterinary care was used
following institutional guidelines, and the procedure was approved
by the Institutional Animal Care and Use Committee (Department
of Physiology, School of Veterinary Medicine, Colorado State
Univ., Ft. Collins, CO). Animals were sacrificed by an intravenous
overdose of pentobarbital. The protocol was approved by the
Institutional Animal Care and Use Committee at Colorado State
University. Isolated VVEC have been shown to: express endo-
thelial cell markers, including vWF, eNOS, and PECAM-1; bind
the lectin Licopercsicon esculentum; and incorporate acetylated low
density lipoproteins labeled with 1,19-dioctadecyl-3,3,39,39-tetra-
methylindo-carbocyanine perchlorate. Cells were grown in high
glucose Dulbeccos Modified Eagle-Medium (DMEM), supple-
mented with 10% fetal bovine serum (FBS), 1% non-essential
amino acids, 100 U/ml penicillin, 100 mg/ml streptomycin,
10 mM L-glutamine, and 30 mg/ml endothelial cell growth
supplement. VVEC were used in the experiments at passage 2–5.
Measurement of endothelial monolayer electrical
resistance
The barrier properties of VVEC monolayers were characterized
using an electrical cell-substrate impedance sensing (ECIS) in-
strument (Applied Biophysics, Troy, NY) as described previously
[15,36,37]. Transendothelial electrical resistance (TER) data were
normalized to initial voltage. The VVEC were seeded in ECIS
arrays until formation of a monolayer for 24–48 h. Before each
experiment, VVEC were incubated with serum-free medium for
2 h. After a baseline measurement, cells were treated with various
concentrations of adenosine or adenosine receptor-specific ago-
nists, and the TER measurement was monitored for 4–6 h. In
other experiments, VVEC were pretreated with the receptor-
specific antagonists for 30 min followed by a treatment with
adenosine or adenosine receptor-specific agonists.
Quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR)
The presence of specific mRNA transcripts for A1R was
evaluated by qRT-PCR. Cellular mRNA was isolated from 3–4
independent isolations of VVEC from control and high altitude-
exposed animals, using an RNease mini kit (Qiagen, Valencia,
CA, USA). cDNA was synthesized from 1 mg of RNA, using an
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA),
according to the manufacturer’s specifications. Quantitative RT-
PCR was performed to measure A1, A2A, A2B, and A3 mRNA
levels, using gene-specific primers: A1 (NM_174497) – sense:
Figure 3. The qRT-PCR analysis of adenosine receptors expression in VVEC. The fold change in mRNA expression of each adenosine
receptor relative to internal housekeeping gene (ß-actin) was calculated. (A) Adenosine receptor mRNA levels were normalized versus VVEC-Co A3R,
whose expression level was arbitrarily established as 1. The results are shown as mean 6 SEM from at least three distinct VVEC populations. Data
were analyzed by one-way ANOVA followed by Tukey’s multiple comparison test for VVEC-Co and VVEC-Hyp separately. (B) Adenosine receptor
mRNA levels in VVEC-Hyp were normalized to VVEC-Co for each gene. Data were analyzed by Student’s t-test. **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0059733.g003
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CACCTTCTTGTTGAGC; A2A (XM_870153) – sense:
CCTCTTCTTCGCCTGCTTTGTCC, antisense:
CCCCGTCACCAAGCCGTTGTACC; A2B (NM_001075925)
– sense: GATCCCCTTCCAGAACTAGGTG, antisense:
TAAAATTTTCACTTTGGGGTCCAG; A3 (NM_001104611)
– sense: CTCCATTGTTACTGCTACGTG, antisense: TAT-
CAAGCCCGATCAGTCCC); and ß-actin (NM_001101) – sense:
GGCACCACACCTTCTACAA, antisense: AGCCTGGATAG-
CAACGTAC. The efficiency of the qRT-PCR for four adenosine
receptors and a housekeeping gene was 93–98%. Equal amounts
of cDNA, equivalent to 5 ng of RNA, were used in each reaction
carried out in iTaq Fast SYBR Green Supermix with ROX (Bio-
Rad, Hercules, CA, USA) using the ABI 7500 Fast Real-time PCR
System (Applied Biosystems, Inc., Foster City, CA, USA). The
relative amount of each gene in each sample was estimated by the
2
2D/DC
T method [38]. The expression of the target genes was
normalized to that of the housekeeping gene, ß-actin, in each
sample.
Depletion of endogenous A1R mRNA using siRNA
VVEC were cultured to 60–70% confluence and transfected
with siRNA specific to A1R (Ambion) or scrambled siRNA as
a control, using siPORT Amine transfection reagent, according to
the manufacturer’s protocol (Applied Biosystems, Carlsbad, CA).
Briefly, cells were serum-starved for 1 h followed by incubation
with 20 nM siRNA for 6 h in a low serum medium. Then, fresh
medium containing 1% serum was added and 42 h later cells were
used in biochemical experiments, ECIS, and/or functional assays.
To confirm the A1R depletion, RNA was isolated using TRIzol,
and the A1R level was analyzed by RT-PCR. For TER
measurement, cells were grown to yield 60–70% confluence in
ECIS arrays and transfected with siRNA, as described previously
[15].
Immunoblotting
Protein extracts were separated by SDS-PAGE, transferred to
the nitrocellulose membrane, and probed with specific antibodies.
Horseradish peroxidase-conjugated goat anti-rabbit IgG antibody
was used as the secondary antibody, and immunoreactive proteins
were detected using an ECL kit according to the manufacturer’s
protocol as previously described [9].
Immunofluorescence microscopy
Immunostaining was performed as described previously [15,36].
Alexa Fluor 488 Phalloidin, a high-affinity filamentous actin (F-
actin) probe, was used to stain actin in VVEC. Images were
captured using a confocal microscope (ZEISS) under high
magnification (1606, Immersion oil).
Statistical analysis
All measurements are presented as the mean 6 SEM of at least
3 independent experiments. To compare results between groups,
a 2-sample Student t test was used. For comparison among groups,
1-way ANOVA was performed. Differences were considered
statistically significant at p,0.05.
Results
Effects of extracellular adenosine on transendothelial
electrical resistance (TER) in VVEC
Our initial observation demonstrated that VVEC-Co and
VVEC-Hyp monolayers exhibit different TER, with lower re-
sistance observed in ‘‘hypoxic’’ cells (Fig. 1). Extracellular
adenosine increased the TER of VVEC-Co in a concentration-
dependent manner (Fig. 2A), indicating barrier enhancement. A
similar but less pronounced effect was observed in VVEC-Hyp
(Fig. 2B). One hundred mM adenosine induced a ,1.7-fold TER
Figure 4. Effects of adenosine receptor agonists on the VVEC barrier function. Activation of A1R improves VVEC barrier function. VVE-Co
(A) and VVEC-Hyp (B) were stimulated with various agonists of adenosine receptors (CCPA, 1 nM; CGS21680, 30 nM; BAY 60-5683 10 nM; IB-MECA,
1 nM) and barrier function was analyzed by TER. VVE-Co (C) and VVEC-Hyp (D) were stimulated with adenosine (Ado, 100 mM) with and without A1R
specific antagonist (PSB 36, 1 nM, 30 min), and barrier function was analyzed by TER. VVE-Co (E) and VVEC-Hyp (F) were stimulated with A1R specific
agonist (CCPA, 1 nM) with and without A1R antagonist (PSB 36, 1 nM, 30 min), and barrier function was analyzed by TER.
doi:10.1371/journal.pone.0059733.g004
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(Fig. 2A). Although the adenosine-induced barrier increase in
VVEC-Hyp was relatively lower, the adenosine mediated increase
in TER was sustained longer in these cells compared to VVEC-
Co, which could be explained by lower initial resistance of VVEC-
Hyp compared to VVEC-Co.
Analysis of expression of adenosine receptors in VVEC by
qRT-PCR
As adenosine plays an important role in strengthening the EC
barrier, we investigated the expression pattern of adenosine
receptors in VVEC. Our qRT-PCR data indicate that both
VVEC-Co and VVEC-Hyp express all four adenosine receptors,
with the highest RNA expression level of A1Rs followed by lower
expression levels of A2B, A2A and A3R (Fig. 3A). Moreover, our
data indicate that the expression of A1Rs is significantly decreased
in VVEC-Hyp compared to VVEC-Co (Figs. 3A and B).
Identification of adenosine receptors involved in the
regulation of VVEC barrier function
We used pharmacological and genetic approaches to define the
adenosine receptors involved in the regulation of the VVEC
barrier function. Minimal effective concentration of each agonist
was used. Agonist-treated cells were subjected to TER assay, as
described above. Our data indicate that CCPA, an A1R-specific
agonist, significantly enhanced the barrier function in both
VVEC-Co and VVEC-Hyp (Figs. 4A and B). Intriguingly, specific
agonists of A2A, A2B, and A3 adenosine receptors, CGS21680,
BAY 60-5683 and IB-MECA, respectively, failed to increase the
barrier function (Figs. 4A and B), indicating a pivotal role of A1
receptors in barrier enhancement function.
In order to demonstrate the involvement of A1Rs in adenosine-
induced barrier enhancement in VVEC, we used a selective
antagonist of A1Rs, PSB-36, as well as specific siRNA. PSB-36
significantly inhibited adenosine-induced TER (Figs. 4C and D).
The effect of the A1R agonist, CCPA, on TER was observed in
both VVEC-Co and VVEC-Hyp, but was much stronger in the
control cells, again suggesting that chronic hypoxia impairs
adenosine-induced VVEC barrier regulation.
In VVEC pretreated with PSB-36 the barrier enhancing effect
of CCPA was significantly attenuated in both VVEC-Co and
VVEC-Hyp (Figs. 4E and F), suggesting that A1Rs play a pre-
dominant role in maintaining VVEC barrier function.
To further investigate the role of A1R in cell barrier function,
VVEC were transfected with a specific and previously validated
siRNA to this receptor. Forty-eight hours after transfection, cells
were stimulated with A1R-specific agonist CCPA, followed by
TER measurement. Our data demonstrate that silencing of A1R
attenuated the effects of CCPA in both VVEC-Co and VVEC-
Figure 5. A1R is involved in adenosine-induced VVEC barrier function. Effect of A1R siRNA on CCPA-induced increase in TER in
VVEC. (A, B) VVEC were incubated with A1R specific siRNA or non-specific siRNA for 48 h and then cells were stimulated with CCPA (1 nM) in TER
measurement assay. The depletion of A1R mRNA and protein was confirmed by RT-PCR (C) and the Western blot analysis with anti-A1R antibody. (D).
Results are presented as mean 6 SE from three independent experiments.
doi:10.1371/journal.pone.0059733.g005
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responsible for the agonist-induced VVEC barrier enhancement.
Control scrambled siRNA had no effect on ligand-induced VVEC
barrier function. We confirmed the A1R expression inhibition at
both RNA and protein levels by RT-PCR (Fig. 5C) and Western
blot (Fig. 5D), respectively.
Role of Gi and Akt signaling in adenosine-induced
enhancement of VVEC barrier function
Previous study demonstrated an involvement of the PI3K/Akt
pathway in regulating endothelial barrier function in large blood
vessels [39]. To test whether this signaling pathway contributes to
adenosine-induced enhancement of VVEC barrier function, cells
were treated with a specific inhibitor of PI3K (LY294002) or Akt
(GSK690693) followed by TER assessment. As shown in Fig. 6,
treatment with LY294002 or GSK690693 significantly attenuated
adenosine-induced enhancement of barrier function in both
VVEC-Co (Fig. 6A) and VVEC-Hyp (Fig. 6B). To further
investigate this signaling pathway, we examined Akt phosphory-
lation by Western blot analysis. Phospho-Akt levels in adenosine-
or CCPA-treated VVEC-Co and VVEC-Hyp were significantly
increased compared to untreated cells (Figs. 7A and C). The
response to CCPA was blunted in the cells pre-treated with PSB-
36, indicating that A1Rs are involved in Akt phosphorylation in
both VVEC-Co and VVEC-Hyp (Figs. 7B and D). As A1Rs are
coupled to Gi proteins, we investigated whether pertussis toxin
(PTx), an inhibitor of Gi-dependent signaling, affects Akt
phosphorylation in response to adenosine or CCPA stimulation.
Pretreatment of VVEC with PTx (100 ng/ml, 18 h) resulted in
a substantial decrease of Akt phosphorylation in both adenosine-
and CCPA-treated VVE-Co (Fig. 7A) and VVEC-Hyp (Fig. 7C).
Distinct roles of actin microfilaments and microtubules in
the barrier-protective effect of adenosine
Several studies documented that the endothelial cytoskeleton
(primarily actin filaments and microtubules) is a critical de-
terminant of vascular integrity and barrier regulation [40,41]. To
test whether the adenosine-induced barrier protective effect is
mediated by stabilization of actin microfilaments or via targeting
of the microtubule cytoskeleton, we studied the effect of adenosine
on VVEC hyperpermeability after actin microfilament disruption
by cytochalasin B or microtubule disassembly by nocodazole.
Cytochalasin B treatment of both VVEC-Co and VVEC-Hyp
resulted in a rapid and dramatic decrease in TER. Treatment with
adenosine at the point when the decrease in TER reached its
lowest point had no protective effect on cytochalasin B-induced
VVEC hyperpermeability (Figs. 8A and B), suggesting that actin
microfilament integrity is required for the barrier-protective effect
of adenosine. Pretreatment of VVEC with nocodazole, a microtu-
bule depolymerizing/disrupting agent, also resulted in a rapid and
dramatic decrease in TER. But in contrast to the effects of
cytochalasin B, nocodazole-induced VVEC permeability was
completely restored by adenosine (Figs. 8C and D), suggesting
that microtubule disruption is not an essential component in
adenosine-induced enhancement of VVEC barrier function.
Analysis of extracellular adenosine-induced actin
cytoskeleton rearrangements
To study the effect of adenosine on the actin cytoskeletal
arrangement in VVEC, we performed an immunocytochemical
analysis of actin filaments. The cell monolayers were treated with
either vehicle or adenosine for 30 min, and Alexa Fluor 488
Phalloidin was used for F-actin staining. Our data indicate that
adenosine treatment significantly increased the polymerized
cortical actin formation in the cell-cell junctions of VVEC-Co
compared to vehicle-treated cells (Fig. 9). Similar, but weaker
adenosine-induced cortical actin formation was observed in
VVEC-Hyp. These data further demonstrate that actin reorgani-
zation may play an important role in adenosine-induced barrier
enhancement in VVEC.
Effect of TNF-a on the VVEC barrier function
TNF-a, one of the most potent pro-inflammatory factors,
regulates vascular endothelial cell permeability through stress fiber
formation and interruption of cellular junctions [42,43,44]. To
analyze the effect of TNF-a on VVEC barrier function, TER was
monitored in cells incubated with TNF-a. Our data indicate that
TNF-a decreased TER in VVEC-Co, which translates to in-
creased cell permeability, and this effect persisted for several hours
(Fig. 10A). In contrast, TNF-a failed to increase the permeability
of the VVEC-Hyp, possibly due to impaired barrier function of
VVEC-Hyp under basal conditions (as indicated in Fig. 1).
Simultaneous addition of TNF-a and adenosine resulted in
a dramatic increase in TER, suggesting that the barrier-protective
effect of adenosine may overcome TNF-a-mediated cell perme-
ability (Fig. 10).
Figure 6. PI3K/Akt pathway mediates adenosine-induced in-
crease in TER in VVEC. VVEC-Co (A) and VVEC-Hyp (B) were pre-
incubated with LY294002 (5 mM; PI3K inhibitor) or GSK690693 (10 nM;
Akt inhibitor) for 30 min and then exposed to adenosine. Barrier
function was measured by TER assay. Results were obtained from three
independent experiments and are presented as mean 6 SE. * p,0.05.
doi:10.1371/journal.pone.0059733.g006
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Exposure to hypoxia induces a vascular leakage leading to
pulmonary edema, vascular inflammation, and angiogenesis. In
our previous study we used a neonatal model of hypoxia-induced
pulmonary hypertension and we demonstrated marked vascular-
ization of the vasa vasorum network that was accompanied by
infiltration and homing of circulating progenitor and inflamma-
tory cells in the pulmonary artery vascular wall [45]. Although
endothelial dysfunction and permeability changes have been
intensively investigated in pulmonary artery endothelial cells, the
mechanisms that control the pulmonary vasa vasorum permeability
remain largely unexplored. As extracellular adenosine is an
important regulator of vascular inflammation and permeability,
in this study we investigated the role of adenosine signaling in
VVEC barrier function. First, we demonstrated differential
expression of adenosine receptors in VVEC originating from
animals kept under normoxic and hypoxic conditions. Second, we
presented adenosine-induced VVEC barrier enhancement. Third,
using highly selective agonists and antagonists, and receptor-
specific siRNA, we established the pivotal role of A1R in VVEC
barrier enhancement. Fourth, we showed that A1R acting via Gi-
mediated Akt activation was involved in adenosine-induced
VVEC barrier enhancement. Fifth, we demonstrated that TNF-
a was unable to further impair barrier function in VVEC-Hyp,
(contrary to VVEC-Co), suggesting that exposure of VVEC to
chronic hypoxia impairs these cells’ permeability. Finally, we
showed a significant attenuation of TNF-a-induced VVEC
permeability upon adenosine treatment, indicative of the barrier-
protective effect of adenosine.
The data on the cell growth/proliferation of both control and
hypoxic VVEC indicate significantly reduced TER in VVEC-Hyp
compared to VVEC-Co from the beginning of the cell spreading
until the formation of monolayers. In addition, the monolayers
Figure 7. Adenosine-induced AKT phosphorylation in VVEC is mediated via Gai. To dissect a role of Gi proteins in Akt activation, VVEC-Co
(A) and VVEC-Hyp (C) were pre-treated with PTx (100 ng/ml, 18 h) and stimulated with 100 mM adenosine (Ado) or 10 nM CCPA for the indicated
periods of time. To determine the role of adenosine A1R in Akt activation, VVEC-Co (B) and VVEC-Hyp (D) were pre-treated with 10 nM PSB 36
(30 min), a specific A1R antagonist, followed by stimulation with 100 mM adenosine (Ado) or 10 nM CCPA for the indicated periods of time. Data are
representative from at least three independent experiments.
doi:10.1371/journal.pone.0059733.g007
Figure 8. Actin microfilament rearrangement is required for the barrier-protective effect of adenosine. (A) VVEC were pretreated with
either vehicle or actin depolymerizing agent, cytochalasin B, for 30 min and then stimulated with adenosine (250 mM). Actin depolymerization rapidly
decreases the TER and completely prevented the protective effect of adenosine in both VVEC-Co and VVEC-Hyp. (B) VVEC were treated with either
vehicle or the microtubule-disrupting agent, nocodazole, for 30 min and then stimulated with adenosine (250 mM). Disruption of microtubules also
decreases the TER rapidly, but failed to alter the adenosine-induced increases in TER in both VVEC-Co and VVEC-Hyp. Results are presented as mean
6 SE and obtained from three independent experiments.
doi:10.1371/journal.pone.0059733.g008
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values in agreement with our previous observation that these cells
are leaky [40] and therefore more fragile to the inflammatory
agents. These data are also consistent with the observations from
the porcine model of pulmonary hypertension, demonstrating that
cells from hypertensive animals showed a higher basal permeabil-
ity than normal cells [46].
Extracellular nucleotides are well recognized as critical
regulators of vascular cell phenotype and function [14,15,17,18],
however, little is known about their role in the regulation of
endothelial barrier function. Previous study has shown that
extracellular ATP exerts a barrier-enhancing effect in human
pulmonary artery endothelial cells [47]. Extracellular adenosine,
a product of ATP hydrolysis, has long been known to play
a protective role against vascular leak under conditions associated
with hypoxia and inflammation. Studies from CD73(2/2) mice
provided evidence that extracellular adenosine reverses hypoxia-
induced vascular leakage in different organs, especially in the lung
[22]. In agreement with previous findings, this study demonstrates
potent concentration-dependent effects of extracellular adenosine
on the VVEC TER. The response was observed in VVEC isolated
from both control and chronically hypoxic animals, but the cells
from control animals exhibited higher amplitude and shorter
duration of the response, whereas the cells from hypoxic animals
exhibited lower amplitude and longer duration of the response,
indicating that hypoxia-induced alterations of cellular mechanisms
involved VVEC barrier function.
Figure 9. Effect of adenosine on actin cytoskeleton in VVEC.
VVEC-Co and VVEC-Hyp were incubated with or without 250 mM
adenosine for 30 min. Actin staining was assessed with a high-affinity F-
actin probe, Alexa Fluor 488 Phalloidin. Immunofluorescence images
were captured using a confocal microscope under 1606magnification
(Immersion oil). Representative cells were selected from groups of
VVEC-Co and VVEC-Hyp.
doi:10.1371/journal.pone.0059733.g009
Figure 10. Effect of TNF-a on the VVEC barrier function. VVEC monolayers (VVEC-Co and VVEC-Hyp) were treated with TNF-a (50 nM) and the
TER was measured in ECIS arrays. Results are presented as mean 6 SE and obtained from three independent experiments.
doi:10.1371/journal.pone.0059733.g010
Figure 11. Schematic representation of the proposed signaling
pathway of adenosine-induced enhancement of barrier func-
tion in VVEC.
doi:10.1371/journal.pone.0059733.g011
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adenosine receptors in hypoxia-induced vascular leak in adenosine
receptor-knockout mice [19,30]. Consistent with this observation,
a recent report indicated that permeability of pulmonary artery
endothelial cells is regulated by A2A and A2B adenosine receptors
and an adenosine transporter, pointing out an importance of both
extracellular and intracellular adenosine [48]. Results from
another study showed that activation of A3R with adenosine
and inosine increased cutaneous vascular permeability [19]. Our
quantitative RT-PCR data indicate that all four adenosine
receptors are expressed in VVEC, with the highest mRNA level
observed for A1R, and the lowest for A3. Using pharmacological
and genetic approaches, we concluded that adenosine’s effect on
VVEC permeability is mediated mostly by A1R, while A2AR,
A2BR and A3R are not likely to be involved. Importantly,
a decrease in expression of A1R in VVEC from hypoxic animals
correlates with a lower TER in VVEC-Hyp compared to VVEC-
Co. The evidence of A1R involvement in barrier protection is also
consistent with an anti-inflammatory role of A1R in several tissues,
and may explain both anti-inflammatory and barrier-protective
functions of A1R in vasa vasorum endothelium. Accordingly, spinal
cords and macrophages from A1R(2/2) mice expressed higher
levels of pro-inflammatory genes in a model of experimental
allergic encephalomyelitis [49], suggesting again that anti-in-
flammatory signals are mediated by A1R. As previously demon-
strated in cell and animal models, A1R was also involved in
protective effects against ischemia/reperfusion cell injury [50,51].
Recent studies reported that A1R in lung microvascular endothe-
lial cells participates in microvascular permeability and leukocyte
transmigration [52], and in anti-inflammatory preconditioning
[53]. Data from animal models also indicate the involvement of
A1R in attenuation of endotoxin-induced lung injury, pulmonary
edema, and alveolar destruction. Activation of adenosine A1 and
A2 receptors have also been shown to reduce endotoxin-induced
cellular energy depletion and oedema formation in the lung [54].
However, our findings are different from the results in human lung
microvascular endothelial cells, which demonstrated a role of
A2AR in adenosine-induced barrier enhancement [36,55]. More
data are needed to establish whether the concentrations of agonists
for the A2A, A2B, and A3R used in our experimental system may
indeed trigger the activation of bovine adenosine receptors.
The mechanisms that modulate endothelial barrier function
were investigated in many studies. In general, the mechanisms that
regulate endothelial barrier enhancement are less understood than
the mechanisms involved in endothelial barrier disruption. Several
ligands, such as sphingosine-1-phosphatase (S1P1), Atrial natri-
uretic peptide (ANP) and Hapatocyte growth factor (HGF), are
reported to enhance or improve endothelial barrier function
[56,57,58]. It was established in various endothelial cell models
that this response involves the activation of cAMP/PKA, cAMP/
exchange protein activated by cAMP (EPAC)/Rab, and/or GSK-
3b/cathenin, leading to junctional integrity and attenuation of
RhoA/ROCK-dependent stress fiber formation [59,60,61,62].
Strikingly, greater paracellular permeability of VVEC-Hyp
compared to VVEC-Co does not correlate with the ability of
VVEC to produce cAMP in response to forskolin [63]. Our
preliminary data also suggest that EPAC is not involved in
adenosine-induced VVEC barrier enhancement (data not shown).
In this study, we provide clear evidence of the involvement of the
Gi/PI3K/Akt pathway in A1R-mediated VVEC barrier enhance-
ment (Fig. 11). Consistent with A1R coupling to Gi, the effects of
adenosine and CCPA were attenuated by pretreatment with PTx,
which prevents Gi-A1R interaction. Since VVEC express PI3Kb
isoform, which is regulated by Gi-derived bc subunits [9],
a contribution of PI3Kb in A1R-mediated VVEC barrier function
cannot be excluded. We propose that the Gi/PIK3b/Akt pathway
represents a novel mode of cytoskeleton remodeling and barrier
regulation in VVEC. These findings can be relevant to better
understanding of fundamental, tissue-specific mechanisms of
microvascular permeability and suggest new therapeutic ap-
proaches for endothelial barrier regulation.
Cortical actin formation is associated with endothelial barrier
enhancement [64]. We demonstrated that adenosine and CCPA
indeed induce cortical actin formation in VVEC. Moreover, we
showed that Akt is involved in adenosine-induced barrier
regulation. Akt has already been linked to cytoskeletal remodeling
in human lung endothelial cells. It was documented that Akt
mediates oxidized phospholipid-induced endothelial barrier en-
hancement by transactivation of the S1P1 receptor, which was
followed by Rac1 activation and cortical actin polymerization
[56]. Among other proteins, the actin interacting protein Girdin
was identified as a novel Akt target contributing to actin
cytoskeleton remodeling during cell migration and lamellipodia
formation [65]. Intriguingly, a recent study demonstrated that
AMPKa1 is co-localized with the adherens junction protein N-
cadherin and contributes to endothelial barrier enhancement [66].
An involvement of PI3K/Akt and possibly AMPK signaling in
A1R-mediated actin cytoskeleton remodeling and barrier regula-
tion in VVEC remains to be investigated.
TNF-a, one of the most potent pro-inflammatory factors,
regulates vascular endothelial cell permeability through stress fiber
formation and interruption of cellular junctions [42,43,44]. TNF-
a expression level and activity can be up-regulated under hypoxia,
inflammation, and pulmonary hypertension [67,68,69,70]. It has
been shown that among several cell types, macrophages and
perivascular adipocytes are potent sources of TNF-a [69,71]. As
the presence of macrophages was observed in pulmonary artery
adventitia of chronically hypoxic animals [10], it can be expected
that TNF-a, may have a paracrine effect on adventitial vasa vasorum
in the pulmonary artery wall. The data from this study also show
that TNF-a decrease the TER in VVEC-Co, and this effect of
TNF-a was blunted by adenosine. Interestingly, TNF-a failed to
decrease TER in VVEC isolated from hypoxic animals. This
suggests a possibility of persistent phenotypical changes in VVEC
in response to chronic hypoxia that could involve TNF-a and
adenosine receptors, as well as components of intracellular
signaling pathways. A possibility of hypoxia-induced changes in
VVEC phenotype is supported by our recently published
observation showing the inability of A2A receptor agonists to
restore barrier function in VVEC isolated from hypoxic, but not
control, animals [63].
In conclusion, in this study we showed for the first time that the
adenosine-induced signaling pathway mediated by Gi-coupled
A1Rs and PI3K/Akt leads to actin cytoskeleton remodeling and to
barrier enhancement in VVEC. In a view of pathologic
consequence of hypoxia-induced vasa vasorum neovascularization
and its function as a conduit for circulating inflammatory cells to
the vascular wall, our data indicate that down-regulation of A1R
in chronic hypoxia may represent a pathological mechanism of
dysregulation of vasa vasorum barrier function. This may lead to
pulmonary vascular remodeling and inflammation, such as that
observed in hypoxic pulmonary hypertension. We propose that
A1Rs can be recognized as a vascular bed-specific and novel
therapeutic target to regulate vasa vasorum barrier function and
pathologic vascular remodeling in chronic hypoxia.
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